Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) Debt to Equity (2023 - 2024)

Oramed Pharmaceuticals' Debt to Equity history spans 2 years, with the latest figure at $0.19 for Q1 2024.

  • For Q1 2024, Debt to Equity changed N/A year-over-year to $0.19; the TTM value through Mar 2024 reached $0.19, changed N/A, while the annual FY2023 figure was $0.31, N/A changed from the prior year.
  • Debt to Equity reached $0.19 in Q1 2024 per ORMP's latest filing, down from $0.31 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.51 in Q3 2023 to a low of $0.19 in Q1 2024.